DiaMedica’s DM-204 Selected for Late Breaking Poster Presentation at the 2012 American Heart Association’s Scientific Conference
27-Sep-2012 (Minneapolis, MN)
DiaMedica (TSX-V:DMA) today announces that it has been selected to present a Late Breaking Science Poster featuring pre-clinical cardiovascular data on DM-204 at the 2012 American Heart Association's Scientific Sessions being held in Los Angeles, CA, November 3-7, 2012.
Mark Williams, PhD., Vice President of Research at DiaMedica will
present the poster presentation titled, "A Novel Bradykinin-2 Receptor
Agonist Antibody that Improves Diabetic and Cardiovascular Endpoints."
DiaMedica is developing DM-204 for the treatment of diabetes and
cardiovascular disease.
“We are delighted to have the opportunity to share the results and
mechanism of our G-protein coupled receptor agonist antibody,” commented
Rick Pauls, Chairman and CEO of DiaMedica. “Cardiovascular disease is a
major complication of diabetes and the leading cause of early death
among people with diabetes. DM-204 could be a promising treatment for
diabetes and cardiovascular disease if it shows the benefit in future
human trials.”
+ Back to All News
About DiaMedica
DiaMedica Inc. (TSX-V:DMA) is a biotechnology company developing first-in-class treatments for the treatment of diabetes. DiaMedica's lead compound, DM-199, is a recombinant human protein for the treatment of both Type 1 and Type 2 diabetes and their complications. The Company is also developing the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the treatment of Type 2 diabetes and cardiovascular disease. DiaMedica’s shares trade on the Toronto Stock Exchange Venture (TSXV: DMA). For more information please visit www.diamedica.com.
For further information please contact:
Rick Pauls
Chairman & CEO
DiaMedica Inc.
Phone: 763-710-4455
Email: info@diamedica.com
Forward-Looking Statements
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica’s expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.